Browsing Tag
Novo Nordisk
84 posts
Magnum Ice Cream (NYSE: MICC) jumps 10.9% on Blackstone and CD&R takeover talk just five months after the Unilever spinoff
Magnum spun out of Unilever at 7.8 billion euros. Froneri sold at 15 billion. Blackstone and CD&R are watching. The summer ice cream season decides the bid.
May 17, 2026
Eli Lilly (NYSE: LLY) bets on oral GLP-1 Foundayo and retatrutide to reclaim its $1tn valuation
Eli Lilly (NYSE: LLY) launched Foundayo, the world's first oral GLP-1 for obesity, in April 2026 and reports Q1 earnings April 30. Full pipeline and risk analysis for retail investors.
April 24, 2026
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Kailera Therapeutics priced its IPO at $16 to raise $625M. Read what the deal means for KLRA, obesity drug competition, and biotech funding now.
April 18, 2026
One pen, four doses, one month: Eli Lilly brings Zepbound KwikPen to Ro’s telehealth platform at $299
Eli Lilly (LLY) partners with Ro to launch the FDA-approved Zepbound KwikPen nationwide. What the $299 self-pay device means for the GLP-1 race. Read more.
April 4, 2026
FDA approves Lilly’s Foundayo as second oral GLP-1 weight loss pill, challenging Novo Nordisk’s head start
FDA approves Eli Lilly's Foundayo (orforglipron), the second oral GLP-1 obesity pill with no food restrictions. What this means for LLY investors and patients. Read more.
April 2, 2026
Torrent Pharma (NSE: TORNTPHARM) enters GLP-1 market with Sembolic and Semalix as over 40 rivals chase semaglutide patent expiry windfall
Torrent Pharmaceuticals launches India's first generic oral semaglutide alongside injectable Sembolic as GLP-1 patent expires. What the pricing and strategy mean. Read more.
March 23, 2026
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
March 21, 2026
NATCO Pharma (NSE: NATCOPHARM) launches cheapest semaglutide in India at Rs 1,290 on Day 1 of patent expiry
NATCO Pharma launches generic semaglutide in India at INR 1,290 on Day 1 of patent expiry. What it means for GLP-1 markets. Read the full analysis.
March 20, 2026
Structure Therapeutics (Nasdaq: GPCR) posts 16% weight loss with oral GLP-1 drug aleniglipron, setting up Phase 3 push
Structure Therapeutics' aleniglipron hits 16% weight loss at 44 weeks in Phase 2, matching injectables. Read the full analysis before Phase 3 begins.
March 16, 2026
HIMS near 52-week low as FDA issues 30 GLP-1 warning letters
FDA sends 30 warning letters to GLP-1 compounders, targeting Hims & Hers Health (HIMS) as regulatory and legal pressure intensifies. Read what it means for investors and the sector.
March 4, 2026